⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ASND News
Ascendis Pharma A/S American Depositary Shares
New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years
globenewswire.com
ASND
Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026
globenewswire.com
ASND
Hall Benefits Law Opens North Carolina and Ohio Offices and Welcomes Wendy Baker and Jeremy Sharp
prnewswire.com
CLF
FE
HNI
ASND
TRU
AYI
MMC
Inaugural Laudio-ASHHRA Report Reveals How HR Leaders Can Strengthen Workforce Stability Through Frontline Leadership
globenewswire.com
ASND
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
globenewswire.com
ASND
Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
globenewswire.com
ASND
Laudio Releases Second Edition of Award-Winning Book for Frontline Healthcare Leaders, “Leader Inspired Work”
globenewswire.com
ASND
Ascendion Named a Market Leader for Agentic Services by HFS Research
prnewswire.com
ASND
Ascendis Pharma to List Ordinary Shares Directly on Nasdaq
globenewswire.com
ASND
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia
globenewswire.com
ASND